A Study of the Intra-Patient Escalation Dosing Regimen With IMCgp100 in Patients With Advanced Uveal Melanoma

NCT02570308 · clinicaltrials.gov ↗

PHASE1,PHASE2

Phase

COMPLETED

Status

146

Enrollment

INDUSTRY

Sponsor class

Conditions

Uveal Melanoma

Interventions

DRUG: IMCgp100

Sponsor

Immunocore Ltd